Keywords: AstraZeneca, Swedish Orphan Biovitrum, Vandetanib, Thyroid cancer, Hemophilia A, USA, Europe, FDA, EMEA, Biogen Idec

US FDA and EMEA accepts AstraZeneca’s filing for vandetanib; SOBI gains orphan status for hemophilia A therapy in EU

Article | 23 September 2010

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the US Food and Drug Administration and the European Medicines ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in